Upcoming Events
Events at a glance
- Grant writing workshop – ECRs and PhD Students in Data Science and AI
- Cambridge New Theraputics Forum (CamNTF)
- 2026 Milner Consortium Call
- Milner Seminar – Focus on Neurodegeneration
- Cambridge New Therapeutics Forum (CamNTF)
Grant writing workshop – ECRs and PhD Students in Data Science and AI
A keynote presentation will be delivered by Dr Mia Sato Tackney, MRC Biostatistics Unit. Hear her story from an awardee of a C2D3 Seed Fund in 2023 to a NIHR Advanced Fellowship in 2025.
Finally we will have a panel discussion from four leading academics, to hear their thoughts on what makes a successful funding application, common pitfalls, and strategies for ensuring your writing is persuasive.
Programme
Registration, Tea and Coffee
Welcome: Professor Zoe Kourtzi, Department of Psychology & Co-Chair C2D3
Elevator pitch practice
Keynote: Success! From C2D3 Seed Fund to Fellowship
- Dr Mia Sato Tackney, MRC Biostatistics Unit, NIHR Advanced Fellow (2025-2030)
Panel discussion: Mastering the art of applications
- Chair: Professor Zoe Kourtzi
- Professor Alexandra Brintrup, Institute for Manufacturing
- Dr Alexis Litvine, Faculty of History
- Dr Anna Moore Winter, Associate Professor, Department of Psychiatry, UKRI Future Leaders Fellow
- Professor Qingyuan Zhao, Department of Pure Mathematics and Mathematical Statistics, Associate Faculty of the Cambridge Centre for AI in Medicine (CCAIM).
Discussion and networking
Registration
Registration is essential and closes Wed 14th January at 17:00
Cambridge New Theraputics Forum (CamNTF)
Theo Chalmers Lecture Theatre, School of Clinical Medicine, Hills Road, Cambridge, CB2 0SP
21st January 2026
18:00 - 20:00
Speakers:
Nataly Hastings, CEO, Cellestial Health, Cambridge - Validating a novel drug target in Parkinson's: Where to begin?
Simon Stott, Director of Research, Cure Parkinson's, London - Developing a new therapy - understanding positioning: A case study in Parkinson's.
Julia Greenland, Neurology Registrar, Addenbrooke's Hospital, Cambridge - Immunosuppression for Parkinson's disease? Learning points from AZA-PD, a randomised controlled trial of azathioprine.
Jonathan Benn, TRIMTECH Therapeutics, Cambridge - Aggregation State Selective Protein Degradation: A Novel Therapeutic Modality for Neurodegenerative Diseases.
Please visit the website
2026 Milner Consortium Call
22nd January 2026
Online Webinar - 10:00
About the Consortium Call
The pharma partners in the Milner Therapeutics Consortium have been working together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing to funded pilot or longer-term collaborations (2-3 years) and are expected to lead to joint publications with the company partners.
The Milner Therapeutics Consortium Call will launch its sixth call for research proposals on 12 January.
Please join the Zoom Q&A webinar on 22 January to find out more and ask questions about the call for proposals.
Milner Seminar – Focus on Neurodegeneration
27th January 2026
16:00 - 17:00
Jeffrey Cheah Biomedical Centre
Please join colleagues from the Milner Therapeutics Institute for their January Seminar, with two fantastic speakers. Presentations and Q&A will be followed by refreshments and networking.
Milner Seminar: Focus on Neurodegeneration
Speakers and talk titles:
Daniel Tams, Astex
“Leveraging Single-Cell Transcriptomics and iPSC Neuron–Microglia Co-Cultures to Probe ALS Mechanisms”
Stefano Pluchino, University of Cambridge
“Advanced Stem Cell Technologies for MS Research and Cure”
Please register by clicking here
Cambridge New Therapeutics Forum (CamNTF)
Jeffrey Cheah Biomedical Centre, Lecture Theatre and Exhibition Space
18th March 2026
16:00 - 20:00
Hosted by the Cambridge Alliance on Medicines Safety (CAMS) and the British Toxicology Society (BTS).
Join us for an insightful event hosted by the Cambridge Alliance on Medicines Safety (CAMS) and the British Toxicology Society (BTS), focused on the safety of advanced therapeutics. This session will bring together leading academic and industry experts to explore challenges, innovations, and regulatory perspectives in this rapidly evolving field and will provide an unique opportunity for local networking.
Title: Safety of Advanced Therapeutics
Speakers include Joel Parry (GSK), Paul Fowler (FStox Consulting Ltd) and Sophie Regan (AstraZeneca).